Three novel radiopharmaceuticals have been evaluated for their potential to be utilized in PET imaging of tau proteins in humans. The results of the study have the potential to improve the way we diagnose and treat Alzheimer’s disease.
Research demonstrates that female mice display a unique pattern of fluctuation in sex hormones during the ovarian cycle that could be linked to cognitive impairments such as Alzheimer’s disease.
Researchers have demonstrated that a DNA vaccine tested in mice is effective at reducing accumulation of tau and beta-amyloid proteins associated with Alzheimer’s disease.
Research presented at SfN has provided insight into the neural risks and benefits of marijuana use, including development and Alzheimer’s disease.
Five studies presented at SfN collectively delve into why a healthy heart and lungs may guard against Alzheimer’s disease and vascular dementia.
In a Phase III clinical trial, a novel drug termed GV-971 has shown promise for improving cognition in people with mild-to-moderate Alzheimer’s disease.
Couldn’t attend the 143rd Annual Meeting of the American Neurological Association? Discover more about the key highlights here.
More evidence reported for causal link between herpes viruses and Alzheimer’s; reinvigorating research into the possible role of infections – and their treatment – in the disease.
A recent study indicates that a chronic periodontal pathogen infection could result in the development of Alzheimer’s disease.
Some EU healthcare systems have been reported to lack the capacity to rapidly move an Alzheimer’s treatment from approval into widespread clinical use.
